Abstract. In animal experiments, adrenal cortical tissue has been successfully regenerated through xenotransplantation of cloned adrenocortical cells, suggesting that the intraadrenal stem cells required for such tissue formation may be present in the adrenal cortex. Stable expression of Ad4BP/SF-1, a key factor for adrenal and gonadal development and steroidogenesis, has been shown to direct embryonic stem cells toward the steroidogenic lineage. However, this steroidogenic capacity was very limited since progesterone was only produced in the presence of an exogenous substrate. Bone marrow mesenchymal cells are thought to contain pluripotent progenitor cells, which differentiate into multiple lineages. We have demonstrated that adenovirus-mediated forced expression of SF-1 in long-term cultured bone marrow cells can produce steroidogenic cells with the capacity for de novo synthesis of various steroid hormones in response to ACTH. This discovery may represent the first step in autologous cell transplantation therapy for patients with steroid hormone deficiency.
ALTHOUGH hormone replacement therapy for patients with adrenal or gonadal failure has been well established, most of these patients require the therapy for their entire lifetime. In addition, these patients are always at risk of developing side effects. The situation is more serious in patients with congenital steroid deficiency, since the replacement therapy has to be started soon after birth and must be continued throughout the patient's lifetime. Furthermore, some patients with endocrine tumors that overproduce biological hormones are not completely cured, even after surgery, or their symptoms are not well controlled by various drugs. Therefore, an innovative therapy that will solve these problems has been anticipated.
Currently, no clinical applications of regeneration medicine or gene therapy have been reported in the whole field of endocrinology, including adrenal or gonadal diseases. However, studies on the ontogenesis and differentiation mechanisms of adrenal and gonadal tissues have been rapidly increasing [1, 2] . Most of the genes responsible for the synthesis and metabolism of steroid hormones have already been revealed [1] [2] [3] [4] [5] (Fig. 1) . Ad4BP/SF-1, whose name is derived from "Ad4-binding protein" (Ad4BP) or "steroidogenic factor-1" (SF-1), is known to be a master regulator in the transcriptional regulation of these steroidogenic enzymes as well as an essential factor for adrenal and gonadal development [1] [2] [3] [4] [5] . Based on these data, several experimental trials of gene therapy or regeneration medicine for adrenal or gonadal tissues have gradually accumulated using in vitro culture systems or animal models. In this review, we provide an overview of recent progress in elucidating the differentiation and Outline of the differentiation mechanism of the adrenal cortex and gonads
The adrenal cortex, gonads, reproductive tracts and kidneys are derived from the intermediate mesoderm.
The mesoderm forms the mesonephros as a basement structure in the early developmental stages of the adrenal cortex and gonads. The early development of the adrenal cortex and gonads is derived from mesenchymal cells attached to the coelomic cavity lining adjacent to the urogenital ridge. These cells originate from the identical origin, namely adrenogenital primordium cells [6] . Thereafter, the common precursor cells divide into two distinct characteristic types of cells, designated adrenal precursor cells and bipotential gonadal precursor cells, and finally develop into the adrenal cortex or testes and ovaries, respectively, under the regulation of many transcriptional factors, including Ad4BP/SF-1 [1, 2] . Signaling pathways via not only transcription factors but also growth factors, such as FGF, have been suggested to be involved in gonadal development [7] . The fetal adrenal cortex is evident from 6-8 weeks of gestation. In the fetal cortex, there are two distinct layers, namely an inner prominent fetal zone and an outer definitive zone, that differentiate into the adult adrenal gland [8] . The fetal cortex occupies 80% of the adrenal cortex area and secretes large amounts of DHEA and DHEA-sulfate, which become substrates for placental estrogen synthesis. The fetal zone shrinks rapidly after birth. In the definitive zone at birth, the zona glomerulosa and zona fasciculata can already be distinguished, and both layers subsequently develop and proliferate. The zona reticularis becomes clear from about 3 years after birth and is almost completed by puberty [8] . On the other hand, sexual dimorphism of the gonads begins between 6 and 7 weeks of gestation with the development of seminiferous cords in the fetal testes. In contrast, histological differentiation of the fetal ovaries is not apparent until 6 months of gestation. As described below, the molecular mechanism of sexual differentiation has been extensively, if not completely, revealed for these two decades of life and clearly indicates that the nuclear receptor Ad4BP/SF-1 is a type of master regulator that controls the overall stream of the developmental mechanism (Fig. 2) .
In humans, it is generally accepted that sex determination is controlled by the presence or absence of the Y chromosome, which carries a gene encoding the StAR, P450scc and 3β-HSD, are expressed in both the adrenals and gonads of humans and mice. P450c21, P450c11 and P450ald are exclusively expressed in the adrenals, but not the gonads of both humans and mice. P450c17 is expressed in both the adrenals and gonads of humans, but in only the gonads of mice. 17β-HSD type 3 in mice and in humans are mostly expressed in the testis.
testis-determining factor (TDF) on its short arm. The TDF has been isolated and designated SRY [9, 10] (Fig.2 ).
On the other hand, little is known about the socalled ovary-determination factor. DAX-1 is considered to be one of the candidates for this factor since it antagonizes SRY function. The expression level of DAX-1 affects sex determination and leads to the dosage-sensitive sex reversal (DSS) phenotype in humans. This assumption is supported by a transgenic study in which male gonads expressing larger amounts of DAX-1 than wild-type gonads showed delayed and incomplete testicular differentiation in mice carrying a weak SRY allele [11] .
Ad4BP/SF-1 was initially identified independently by Morohashi and Parker as a ubiquitous transcription factor for steroidogenic hormones [1] [2] [3] [4] [5] . Ad4BP/SF-1 binds as a monomer to its responsive element located in the promoter of steroidogenic genes and enhances their transcriptional levels [1] [2] [3] [4] [5] . In addition, the cAMP-protein kinase A (PKA) signal pathway can SF-1, steroidogenic factor 1; StAR, steroidogenic acute regulartory protein; WT-1, Wilmus' tumor-related gene; DSS, dosagesensitive sex reversal; DAX-1, DSS-adrenal hypoplasia congenital gene; SOX9, SRY-related genes HMG-box 9; AR, androgen receptor; ER, estrogen receptor; E2, estradiol; DHT, dihydrotestosterone; LRH-1, liver receptor homologue 1; MIS, Mullerian inhibiting substance strongly potentiate Ad4BP/SF-1 transactivation activity [12] . Since knockout mice for Ad4BP/SF-1 show agenesis of both the adrenal glands and the gonads [13, 14] as well as decreased expression levels of luteinizing hormone (LH and follicle stimulating hormoneFSH in the pituitary gonadotroph [14, 15] , Ad4BP/SF-1 has been considered to be an essential factor for differentiation of the pituitary-adrenal or -gonadal axis. DAX-1 is also an important factor for the development of this axis since patients with DAX-1 mutations show Xlinked adrenal hypoplasia congenital (AHC) and hypogonadotropic hypogonadism [16, 17] . DAX-1 is considered to be involved in the differentiation process of the fetal adrenal gland, since the adrenal glands obtained at autopsy from patients with AHC are very similar to those in the fetal adrenal cortex and do not include the permanent (adult) cortex structure [18] . Although their exact roles in humans are unknown, many other factors, such as, Wnt4, Cited 2, PBX-1 [1] , M33 [19] , Fgf 9 [20] , Dhh [21] and Gata4 [22] , are also known to be involved in adrenal or gonadal development since disruption or overexpression of these genes in mice causes sex reversal or delayed sexual differentiation [2] .
Transplantation, regeneration and gene therapy for the adrenal or gonadal glands
Candidate diseases for such cutting-edge medicine will be various diseases involving adrenal enzyme deficiencies (single gene diseases), chronic adrenal failure, adrenal cancers, intractable Cushing syndrome, etc.
(1) Trial of transplantation, regeneration and gene therapy for the adrenal glands Hornsby et al. reported that transplantation of cloned cells from bovine adrenocortical cells into severe combined immunodeficiency (SCID) mice resulted in the formation of adrenal gland-like tissue, which successfully compensated for adrenal failure after bilateral adrenalectomy [23] . Furthermore, these authors succeeded in immortalizing the cloned cells by expressing telomerase reverse transcriptase (TERT) and noted similar successful compensation of adrenal failure in adrenalectomized SCID following transplantation of the immortalized cells [24] . These reports indicate the existence of intraadrenal stem cells. Although the above mechanism is currently unclear, it is speculated that xenotransplanted adrenal cell grafts may promote angiogenesis at the transplantation site, leading to accelerated cell proliferation to form the adrenal gland [25] . In addition, mice survived for more than 16 days and the normal adrenocortical structure was observed when human adrenal cells and 3T3-L1 cells, which produce FGF, were co-transplanted into the subcapsular region of the kidneys of adrenalectomized mice [26] . Interestingly, in a trial of autologous transplantation of single adrenocortical layer cells into the subcapsular region of the kidneys of adrenalectomized mice, transplantation of zona glomerulosa cells resulted in the formation of new adrenocortical tissue, which was composed of cells that were histologically similar to those of the zona glomerulosa and zona fasciculata. However, when zona fasciculata cells were transplanted, no such structure was formed [27] . These findings are very interesting with respect to the stem cell origin of the adrenal cortex and the zonation. An undifferentiated zone between the zona glomerulosa and zona fasciculata has been suggested to be an adrenocortical stem cell zone, which expresses SF-1 [28] . Cell migration and differentiation are thought to occur from within this stem cell zone, although factors regulating this regeneration process remain unknown. While adrenal cell transplantation into the subcapsular region of the kidneys leads to good regeneration of adrenal cortical tissue, cell transplantation into the skin has also been reported to be possible when a collagen gel is used [29] . Although previously denied, autologous transplantation of adrenocortical cells or tissues does actually cause innervation, which is correlated with the degree of recovery of the steroid production [30] . Crawford et al. demonstrated that stable SF-1 expression in ESCs resulted in a steroidogenic capacity and adenosine 3,5-cyclic monophosphate (cAMP) or retinoic acid-dependent inducibility of cytochrome P450scc, leading to progesterone production [31] . In this experiment, SF-1 initiated the program toward steroidogenic cells through a process that clearly did not require embryoid body formation. However, this steroidogenic capacity was restricted at the stage of progesterone synthesis, and did not occur as de novo synthesis, since the addition of an exogenous substrate, 20α-hydroxycholesterol, which bypasses the mitochondrial outer membranes, was required for progesterone production. In addtion, the converted cells were not responsive to adrenocorticotropic hormone (ACTH) or human chorionic gonadotropin (hCG). Nevertheless, these results clearly indicate that SF-1 is a key factor in steroidogenic cell differentiation. The diffierence between steroidogenic ES cells and steroidogenic tissue may partly arise because SF-1 is not expressed until around E9 [32] , after the urogenital mesoderm has been separated from pluripotent cellular lineage. Early differentiation step before SF-1 expression may be necessary to drive to form normal steroidogenic cells.
Apart from the steroidogenic capacity, ES cells has been shown to differentiate into functional germ cells that can participate in spermatogenesis when transplanted ito reconstituted testicular tubules [33] .
(3) Trial of steroid-producing cell regeneration from BMCs
A number of studies have suggested that, following transplantation into different tissues, BMCs may contribute to the regeneration of hematopoietic or mesenchymal lineages in multiple organs [34] [35] [36] [37] . Although these potential effects may partly occur through spontaneous cell fusion with recipient cells [38, 39] , BMCs certainly contain pluripotent progenitor cells, which can differentiate into multiple lineages. We therefore tested whether the introduction of SF-1 into mouse BMCs could produce steroidogenic cells [40] .
We expanded a relatively pure BMC population by culturing the cells for 120-180 days, and then investigated the steroidogenic properties of the cells after infection with Adx-bSF-1. Flowcytometric analyses revealed that the steroidogenic BMCs were negative for the surface markers CD45 (hematopoietic cells marker), CD11b (monocyte/macrophage marker) and CD44 (a potential marker for mouse mesenchymal cells) but positive for c-kit and Sca-1, which are hematopoietic and mesenchymal stem cell/progenitor markers. Surprisingly, the BMCs infected with AdxbSF-1 produced significant amounts of progesterone (P4), deoxycorticosterone (DOC), corticosterone (B), 17α-hydroxyprogesterone (17α-OH P4), 11-deoxycortisol (S), dehydroepiandrosterone (DHEA), ∆4-androstenedione (∆4-A) and testosterone (T), while those infected with Adx-LacZ did not (Fig. 3A) . Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) of the cells revealed the presence of steroidogenic acute regulatory protein (StAR), P450scc, 3β-hydroxysteroid dehydrogenase (3β-HSD), P450c11, P450c17 and 17β-HSD type 3 mRNAs in BMCs infected with Adx-bSF-1, but in those infected with Adx-LacZ (Fig. 3B) . Interestingly, the BMCs originally expressed adrenocorticotropic hormone receptor (ACTH-R), a receptor type transcribed in adipose tissues [41] but not in adrenal glands [42] . In fact, ACTH dose-dependently stimulated the production and secretion of progesterone by BMCs infected with Adx-bSF-1 (Fig. 4A) , but not by BMCs infected with Adx-LacZ. The induction of the mRNAs for the respective steroidogenic enzymes following treatment with 2.4 µM ACTH was also confirmed by real-time PCR [40] . Surprisingly, the significant production of DOC was observed until at least 112 days (Fig. 4B) , despite the fact that the half-life of the adenovirus was 2-3 weeks and there was no induction of endogenous mouse SF-1. This unexpected result may be explained by the possibility that continuous bSF-1 expression after adenovirus infection, even at low levels, is sufficient to maintain long-term steroid production by BMCs. Another possibility is that SF-1 expression may be indispensable for the initiation of steroidogenesis via the induction of steroidogenic enzymes, but not critical for its maintenance.
The steroid profile of the cultured BMCs showed a mixed pattern of mouse adrenal and gonadal steroidogenesis, namely simultaneous production of DOC, B, DHEA, ∆4-A and T. Interestingly, P450c17 is expressed in the human adrenal gland, but not in the mouse adrenal gland. Therefore, the significant expression of P450c17 in BMCs indicates a mixed steroid profile beyond the species level, suggesting the possibility of a common origin for steroidogenic tissues, namely stem cells. Although little is known about the origin of the stem cells, a previous study on the expression profile of SF-1 indicated that the undifferentiated adrenal cortex and gonads of early stage fetuses originate from a common adrenogenital primordium [6] . The multipotency of BMCs to differentiate into either adrenal or gonadal steroidogenic cells provides an important model for future clarification of the mechanisms of tissue-, zone-or cell-specific adrenal and gonadal steroidogenic cell differentiation. One plausible speculation may be that bone marrow-derived stem cells settle in the adrenocortical stem cell zone, where SF-1 expression may become possible.
Although the character of mouse mesenchymal stem cells has not been fully clarified and remains controversial [43, 44] , steroid-producing cells may originate from multipotent and immature stem cells. Importantly, long-term cultured BMCs were able to differentiate into an osteoblastic phenotype following appropriate treatment, suggesting that the character of the steroidogenic cells may be much closer to mesenchymal BMC lineages [45] . However, the exact origin of these steroidogenic cells remains unclear and warrants further investigation. Similar to our data, a recent report demonstrated that cAMP stimulation of a cloned mouse BMC line, KUM9, stably expressing SF-1 induced cell differentiation into cells with a testis-type steroidogenic capacity [46] . In addition, mouse BMCs were reported to be able to differentiate to Leydig-type cells in an in vivo environment, although a possibility of cell fusion cannot be completely excluded [46] . A trial of gene therapy for adrenal diseases (in vitro and animal models)
Congenital adrenal hyperplasia is caused by genetic defects in adrenal steroidogenic enzymes, and represents a good target for gene therapy. Tajima et al. reported that direct injection of an adenovirus containing P450c21 into the adrenal glands of 21-hydroxylasedeficient mice resulted in a high level of intraadrenal expression of P450c21 for 2-7 days after the injection, although the expression level gradually decreased thereafter [47] . It was confirmed that the zonation of the adrenal glands disappeared after the injection. Although long-lasting expression was not obtained, the data suggest a possible application to gene therapy for 21-hydroxylase deficiency. Another previous trial used a sheep model to introduce a desirable gene in the fetal period by direct injection of an adenovirus into the umbilical vein under an ultrasonic wave guide and confirmed a high level expression of the transduced gene in the liver and adrenal glands [48] . These observations suggest a possible application to gene therapy for congenital adrenal hyperplasia (CAH) in the fetal period. Adenoviruses are easily incorporated into the liver, but they also show comparatively good uptake into the adrenal glands [49] . A detailed investigation into the effects of various adenovirus variants regarding the introduction efficiency and responsiveness to ACTH of bovine adrenocortical cells has been reported [50] . This report states that although the E1/E3-deficient type of adenovirus was optimal for the introduction efficiency into bovine adrenocortical cells, it lowered their responsiveness to ACTH. On the other hand, the E3/E4-deficient type showed low introduction ability, but the cells maintained a good responsiveness to ACTH. The authors concluded that since steroids are stress-responsive hormones, the E4-deficient adenovirus should be recommended for adrenal diseases based on the importance of ACTH responsiveness. Chuman et al. found that the promoter of P450c11 induced a suicide gene in human adrenocortical cancer cells. Furthermore, they constructed a system to augment adrenal-specific expression of this suicide gene by combination with the enhancer element of P450c11. When they introduced a herpes simplex virus thymidine kinase (HSV-TK) into this expression system, HSV-TK was strongly induced by cAMP and ACTH [51] . HSV-TK has the ability to change nontoxic drugs, such as ganciclovir, to toxic phosphorylated chemical compounds. In fact, when HSV-TK is specifically expressed in adrenal cancer cells, the cells become sensitive to ganciclovir. These observations are interesting since they suggest a possible application to gene therapy for adrenal cancer.
Conclusions and future directions
Regeneration medicine for the adrenal cortex by xenograft transplantation of cloned adrenocortical cell clusters may be a promising therapy, but it is still very preliminary and based on animal experiments. Much future effort to obtain vascularized functional tissues and overcome immunological rejection will be needed. Our finding that introduction of SF-1 into long-term cultured BMCs leads to transformation into steroidogenic cells, which are in a basal state as well as responsive to ACTH and capable of producing multiple steroid hormones, will also provide an innovative therapeutic tool for patients suffering from steroid insufficiency like adrenal insufficiency and male or female hypogonadism, since it indicates that autologous BMC transplantation is possible. In addition, this tool may be also applicative to the therapy of autoimmune diseases which sometimes requires glucocorticoids (Fig.  5) . However, it remains unclear whether Ad4BP/SF-1 is sufficient to realize ideal steroidogenic cells, since many other factors are involved in cell differentiation and steroidogenesis (Fig. 2) . Ad4BP/SF-1 is clearly essential for the production of steroidogenic stem cells, as evidenced by our study and also by the fact that the phenotype of homozygous SF-1 KO mice shows agenesis of both adrenal glands and gonads [13, 14] , but this may not be sufficient to produce adrenal-or gonadal-specific cell types. However, a more predominant dosage-sensitive effect of SF-1 on adrenal rather than gonadal formation has been suggested from a finding of the predominant reduction of adrenal size in heterozygous SF-1 KO mice [52] . A similar finding has recently been reported in an experiment that Ad4BP/SF-1 transgenic mice harboring varied expression levels of SF-1 among tissues were applied to rescue homozygous Ad4BP/SF-1 KO mice; the transgenic mice failed to rescue the adrenal gland, but successfully rescued the gonad and spleen [53] . Therefore, one approach to direct the steroidogenic cell lineage might be to control Ad4BP/SF-1 expression levels or Ad4BP/SF-1 transcriptional activity in BMC cells. Relatively less expression of Ad4BP/SF-1 might lead to the production of gonad-type steroidogenic cells but this might not be enough to provoke adrenal-type steroidogenic cells. However, it is also important that efforts be made to identify unknown factors that might determine the tissue-specific steroidogenic cell type; such factors would be useful to modify the cell type of BMC cells, adrenal or gonadal type cells. The multipotency of BMCs to differentiate into adrenal or gonadal steroidogenic cells may provide a key model for solving the mechanism of the determination of the direction of steroidogenic cell type differentiation into the adrenal cortex or gonads in the future (Fig. 5) .
It may be possible to source the mesenchymal stem cells from adipose tissue. However, our results are very preliminary and for future clinical applications, we need to reconsider the choice of vector from the viewpoints of safety and efficacy. As far as adenoviruses are concerned, the situation does not appear to be so optimistic with respect to their safety in humans and limited efficacy due to their short half-life. An alternative choice to solve these problems would be to transform mesenchymal stem cells into steroidogenic cells by some humoral factors without exogenous expression of any gene including SF-1. Research in this field has only just begun and is expected to develop extensively in the near future, in order to relieve the many patients who are forced to take hormone replacement therapy.
